Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27602895 | 0.94 | GPR84 (0.45) | CA1GPR84FFAR1SLC1A2SLC1A1 | |
| SCHEMBL28343444 | 0.92 | GPR84 (0.48) | CA2GPR84FFAR1MAPTLCK | |
| SCHEMBL28187499 | 0.92 | GPR84 (0.48) | CA2GPR84FFAR1MAPTLCK | |
| SCHEMBL1463207 | 0.86 | — | — | |
| SCHEMBL7207177 | 0.84 | CA2 (0.41) | CA2MAPK1CA1FDPSLMNA | |
| SCHEMBL27617573 | 0.84 | CA2 (0.38) | CA2MAPK1CA1ACHEBACE1 | |
| SCHEMBL10878549 | 0.83 | CA2 (0.39) | CA2MAPK1CA1FDPSLMNA | |
| SCHEMBL7686574 | 0.83 | ALDH1A1 (0.41) | CA2MAPK1CA1FDPSLMNA | |
| SCHEMBL31302726 | 0.82 | PPARG (0.50) | FFAR1MAPTPPARDLMNA | |
| SCHEMBL31302713 | 0.82 | PPARG (0.50) | FFAR1MAPTPPARDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-RE38333-E1 | Making tenofovir analogs and salts; use as viricides for HIV, retroviruses | GILEAD SCIENCES, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-0915894-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6069249-A | CHEMICAL INTERMEDIATES; DETECTION LABELS FOR NUCLEOTIDE PROBES | GILEAD SCIENCES, INC. (US) | 2000-05-30 | — | — | US | disclosed |
| US-6043230-A | Use of tenofovir disoproxil fumarate in treatment of HIV | GILEAD SCIENCES, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5977089-A | ORALLY ADMINISTERING TENOFOVIR DERIVATIVES | GILEAD SCIENCES, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5922695-A | COMPOUNDS CONTAINING CARBONATE OR CARBAMATE GROUPS | GILEAD SCIENCES, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0915894-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004569-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | CA2 1659/4885MAPK1 4548/4885CA1 2554/4885 |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | CA2 1659/4885MAPK1 4548/4885CA1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.